December 11th, 2017
jobs
homes

Menu
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Clearmind Medicine Inc.

< Previous 1 2 3 4 Next >
Clearmind Medicine Announces First US Site for its Phase I/IIa Clinical Trial Evaluating CMND-100 in Patients with Alcohol Use Disorder
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND CSE:CMND
Clearmind Medicine Announces Receipt of Nasdaq Minimum Bid Price Notification
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND CSE:CMND
Clearmind Medicine to Host Virtual Investor Conference on Psychedelics for Obesity
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND CSE:CMND
Clearmind Medicine Announces IRB Approval to Conduct Clinical Trial on Alcohol Use Disorder
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND CSE:CMND
Clearmind Medicine Retains Crescendo Communications LLC. for Investor Relations and Announces Granting of Stock and Warrants
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND CSE:CMND
Clearmind Medicine Strengthens Scientific Advisory Board with Appointment of Prof. Joseph Tam
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND CSE:CMND
Clearmind Medicine Announces Clinical Supply Agreement for its Upcoming Clinical Trial
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND CSE:CMND
Clearmind Medicine Forms a Data and Safety Monitoring Board to Oversee its First-in-Human Clinical Trial
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND CSE:CMND
Clearmind Medicine Expanding IP Portfolio with New US Patent Application for Treatment of Depression
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND CSE:CMND SPRC
Clearmind Medicine Engages Experienced Contract Research Organization to Support its First-in-Human Clinical Trial
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND CSE:CMND
Clearmind Medicine Closes US$3.5 Million Public Offering
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND CSE:CMND
Clearmind Medicine Announces Pricing of US$3.5 Million Public Offering
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND CSE:CMND
Clearmind Medicine Submits IND Application to FDA for its Proprietary CMND-100 Treating Alcohol Use Disorder
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND CSE:CMND
Clearmind Medicine Appoints Professor Henry R. Kranzler, M.D., to Scientific Advisory Board
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND CSE:CMND
Israel-Based Clearmind Medicine Files Patent Applications for Three Unique Combinations of Future Psychedelic-Based Compounds
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND CSE:CMND SPRC
Israel-Based Clearmind Medicine Strengthening IP Portfolio with Three Provisional Patent Applications in the US
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND CSE:CMND SPRC
Israel-Based Clearmind Medicine to Present at The OurCrowd Global Investor Summit Sponsored by Greenberg Traurig Tel Aviv
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND CSE:CMND
Israeli- Based Clearmind Medicine to Host Virtual Investor Conference on Psychedelics for Obesity
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND CSE:CMND
Israeli Biotech Clearmind Medicine Announces Positive Pre-Clinical Results Treating Major Depression With a Novel Ketamine-Based Compound
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND CSE:CMND
Hebrew University' Yissum and Israeli Biotech Clearmind Medicine’s Psychedelic-Derived Obesity Treatment Presented by Professor Joseph Tam, D.M.D., Ph.D. at Isranalytica 2023
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND CSE:CMND
Israel-Based Clearmind Successfully Completed Two R&D Projects With The Hebrew University of Jerusalem’s Tech Transfer Company, Yissum
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND CSE:CMND
Israel-Based Clearmind Announces Additional Positive Results from the Third Part of its Pre-Clinical Study for Cocaine Addiction Treatment
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND CSE:CMND
Israel-Based Clearmind Medicine Successfully Completes Production of CMND-100 Drug Candidate for Clinical Trial
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND CSE:CMND
Israel-Based Clearmind Medicine Shows Efficacy of Psychedelic- Derived Obesity Treatment in Pre-Clinical Trial
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND CSE:CMND
Clearmind Medicine Announces Shareholders Meeting Results
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND CSE:CMND
Israel-Based Clearmind Medicine Announces First Clinical Center to Join Its Clinical Trial for Alcohol Use Disorder
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND CSE:CMND
Israel- Based Clearmind Medicine Granted U.S. Patent for Psychedelic-Based Alcohol Substitute
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND CSE:CMND
Israeli Based Biotech Company Clearmind Medicine Inc’s CEO, Dr. Adi Zuloff-Shani, Issues Letter to Shareholders
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND CSE:CMND
Israeli Based Biotech Company Clearmind Completes IND-Enabling Studies for CMND-100
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND CSE:CMND
Israeli Biotech Clearmind Medicine Appoints ex-Red Bull Executive Special Advisor for Developing MEAI as Alcohol Substitute
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND CSE:CMND
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.